Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma

A. M. Capotorto, L. Pavesi, P. Pedrazzoli, G. A. Da Prada, C. Zamagni, B. Massidda, A. Farris, A. Martoni, G. Lelli, G. Robustelli Della Cuna

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences